Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease

被引:80
作者
Davis, Benjamin M. [1 ]
Pahlitzsch, Milena [1 ]
Guo, Li [1 ]
Balendra, Shiama [1 ]
Shah, Parth [1 ]
Ravindran, Nivedita [1 ]
Malaguarnera, Giulia [1 ]
Sisa, Claudia [1 ]
Shamsher, Ehtesham [1 ]
Hamze, Hisham [1 ]
Noor, Abdinasir [1 ]
Sornsute, Acom [2 ]
Somavarapu, Satyanarayana [2 ]
Cordeiro, M. Francesca [1 ,3 ]
机构
[1] UCL Inst Ophthalmol, London EC1V 9EL, England
[2] UCL Sch Pharm, London WC1N 1AX, England
[3] Imperial Coll London, Western Eye Hosp, ICORG, London NW1 5QH, England
来源
SCIENTIFIC REPORTS | 2018年 / 8卷
关键词
RETINAL GANGLION-CELLS; SOLID LIPID NANOPARTICLES; I CLINICAL-TRIAL; OPTIC-NERVE; AMYLOID-BETA; OXIDATIVE STRESS; HYPOXIA; PRESSURE; GLAUCOMA; DELIVERY;
D O I
10.1038/s41598-018-29393-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5dione) is a polyphenol extracted from turmeric that has long been advocated for the treatment of a variety of conditions including neurodegenerative and inflammatory disorders. Despite this promise, the clinical use of curcumin has been limited by the poor solubility and low bioavailability of this molecule. In this article, we describe a novel nanocarrier formulation comprising Pluronic-F127 stabilised D-a-Tocopherol polyethene glycol 1000 succinate nanoparticles, which were used to successfully solubilize high concentrations (4.3 mg/mL) of curcumin. Characterisation with x-ray diffraction and in vitro release assays localise curcumin to the nanocarrier interior, with each particle measuring < 20 nm diameter. Curcumin-loaded nanocarriers (CN) were found to significantly protect against cobalt chloride induced hypoxia and glutamate induced toxicity in vitro, with CN treatment significantly increasing R28 cell viability. Using established glaucoma-related in vivo models of ocular hypertension (OHT) and partial optic nerve transection (pONT), topical application of CN twice-daily for three weeks significantly reduced retinal ganglion cell loss compared to controls. Collectively, these results suggest that our novel topical CN formulation has potential as an effective neuroprotective therapy in glaucoma and other eye diseases with neuronal pathology.
引用
收藏
页数:13
相关论文
共 93 条
  • [91] Yue Y.-K., 2014, J OCUL PHARMACOL TH, P1
  • [92] The Role of Peroxisome Proliferator-Activated Receptor and Effects of Its Agonist, Pioglitazone, on a Rat Model of Optic Nerve Crush: PPARγ in Retinal Neuroprotection
    Zhu, Juming
    Zhang, Junfang
    Ji, Min
    Gu, Hongwei
    Xu, Yue
    Chen, Chen
    Hu, Nan
    [J]. PLOS ONE, 2013, 8 (07):
  • [93] Muscarinic activation attenuates abnormal processing of β-amyloid precursor protein induced by cobalt chloride-mimetic hypoxia in retinal ganglion cells
    Zhu, Xu
    Zhou, Wei
    Cui, Yongyao
    Zhu, Liang
    Li, Juan
    Xia, Zheng
    Shao, Biyun
    Wang, Hao
    Chen, Hongzhuan
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 384 (01) : 110 - 113